JYNNEOS Vaccine Commercial Transition

As of April 1, 2024, JYNNEOS mpox vaccine is commercially available.  As an ACIP-recommended vaccination for high-risk people 18 years and older, the vaccine is covered under Medicare and Medicaid and is expected to be covered by private payers. The commercial distribution of JYNNEOS is in cartons of 10 single-dose vials (carton NDC number: 50632-001-03). This is a different carton NDC than the 20-pack of single-dose vials (carton NDC number: 50632-001-02) currently distributed by HHS. 

During the transition to commercial supply, providers may continue to access the HHS JYNNEOS supply as commercial availability ramps up, especially to support access in circumstances in which commercial supply is not yet accessible. Health departments should continue to leverage any remaining HHS-supplied inventory that was previously distributed to support access. Additional ordering of HHS supply through HPOP will continue as needed. On April 30, 2024 at 9:00 AM, all current thresholds will be set to zero. If additional supply is needed after that time, jurisdiction and federal entity partners can use the established OOC request process. On or near August 1, 2024, HHS anticipates that requests and ordering of USG-procured JYNNEOS will fully close.

Any mpox vaccine distributed by HHS can not be submitted for reimbursement of acquisition costs. It is the responsibility of our SLTT and federal entity partners, as well as the responsibility of individual providers, to ensure there is no payment sought for supply that was received at no cost from HHS.